June 4, 2017 — Cynvenio presented preliminary data from the first year of our 211-patient TNBC clinical research study in a poster titled, “Use of serial multi-template liquid biopsies in triple negative breast cancer monitoring” by Dr. Paul Y. Song et. al. at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
This study examines the utility of serial liquid biopsies using a multi-template approach—identification and analysis of cell-free DNA (cfDNA) and circulating tumor cells (CTCs)—as a solution.
- 77% of post-treatment TNBC patients were found to have had evidence of genomic mutations in at least one sample, but did not show these changes in consecutive blood draws and have not experienced documented recurrence.
- 6.7% of the group did show changes in both cfDNA and CTC’s on consecutive blood draws and have developed documented evidence of recurrence.
- Patients who had the same mutation in two consecutive draws had a 3.3x greater chance of developing recurrence compared to those found to have mutations on only one draw.
- cfDNA mutations were found in 22.84% of the draws, CTC mutations in 19.84%, and both cfDNA and CTCs mutations in 4.28%, reinforcing the need for a multi-template approach to find and track mutations.
"The preliminary data shows the importance of a multi-template approach to provide greater visibility on a patient’s tumor landscape and the ultimate value of longitudinal monitoring to track persistent mutations."
— Paul Y. Song, MD, Chief Medical Officer of Cynvenio